Akari Therapeutics Plc (AKTX) AI Stock Summary

Cash runway under 2 months with expected impairment

Updated May 22, 2026

Snapshot

Akari Therapeutics is a clinical-stage biotech with no revenue and a strained balance sheet. The company burned $17.3 million in net income during FY 2025 and holds only $5.2 million in cash. At its current burn rate, that cash lasts approximately 1.5 months. The company recently raised $5.5 million through a private placement, which extends the runway but comes with significant dilution. The stock is trading near its 52-week low, having fallen 91% from its peak. A recent 1-for-40 reverse split and a delayed quarterly filing citing a material impairment charge signal deep financial stress. While the company has analyst support and positive preclinical data for its lead cancer drug, AKTX-101, the immediate risk of running out of cash or needing further dilutive financing is high.

What's Happening Right Now

Thu 21st May '26 · Financing: Akari priced a $5.5 million private placement to fund its lead cancer drug candidate, AKTX-101, toward a Phase 1 trial.
Thu 21st May '26 · Preclinical Data: Akari reported positive preclinical data showing its lead drug works synergistically with existing KRAS inhibitors in pancreatic cancer models.
Mon 18th May '26 · Filing Delay: The company delayed its quarterly report and warned of a material non-cash impairment charge due to its collapsing market value.
Mon 6th Apr '26 · Partnership: Akari announced a strategic partnership with WuXi XDC to accelerate the development of its novel antibody-drug conjugate payload.
Tue 17th Mar '26 · Reverse Split: The company executed a 1-for-40 reverse stock split in March 2026, a move typically taken by stocks under severe price pressure.

Bottom Line

Akari Therapeutics is a high-risk biotech play with a very short cash runway. The company has no revenue and is burning cash faster than it can generate it, forcing it to raise money through dilutive financing. The recent reverse split and delayed filings are warning signs of financial distress. While the science behind its lead drug looks promising in early tests, the business is not yet self-sustaining. A reader should view this as a speculative bet on clinical success, not a stable investment, and be prepared for further share dilution or cash crunches.